目的比较白介素13(IL—13)在慢性鼻窦炎不伴鼻息肉(CRSsNP)和慢性鼻窦炎伴鼻息肉(CRSwNP)患者中的差异性表达。方法选取10例CRSsNP和20例CRSwNP患者作为研究对象。根据鼻窦CT反映的病变范围评估患者病情,采用模拟视觉量表(VAS)评估慢性...目的比较白介素13(IL—13)在慢性鼻窦炎不伴鼻息肉(CRSsNP)和慢性鼻窦炎伴鼻息肉(CRSwNP)患者中的差异性表达。方法选取10例CRSsNP和20例CRSwNP患者作为研究对象。根据鼻窦CT反映的病变范围评估患者病情,采用模拟视觉量表(VAS)评估慢性鼻窦炎轻重程度;术后采用PCR法分析IL-13在CRSsNP和CRSwNP组患者鼻黏膜及息肉中的差异性表达。结果 CRSwNP组鼻息肉组织IL-13 m RNA表达明显高于临近黏膜及CRSsNP黏膜组织;CRSsNP组和CRSwNP组鼻窦黏膜组织IL-13 m RNA表达差异无统计学意义。结论 IL-13m RNA表达水平在CRSsNP和CRSwNP组患者鼻黏膜或息肉中存在差异;白介素13(IL—13)在慢性鼻窦炎伴鼻息肉的病理过程中发挥有重要的作用。展开更多
Aspirin-exacerbated respiratory disease(AERD)patients with CRSwNP suffer from reduced quality of life,reduced economic productivity,and higher risk of depression and sleep dysfunction.These patients often require freq...Aspirin-exacerbated respiratory disease(AERD)patients with CRSwNP suffer from reduced quality of life,reduced economic productivity,and higher risk of depression and sleep dysfunction.These patients often require frequent medical and surgical therapy,including functional endoscopic sinus surgery for recalcitrant disease.Given this severity,anti-type 2 biologic treatments are being investigated for use in this subgroup of patients with CRSwNP,including Omalizumab and Dupilumab.Preliminary data suggests that SNOT-22 related quality of life improvements following treatment with biologies are comparable to the current standard of care in the short term,but there is a lack of long-term data and standardized regimen that makes direct comparison difficult.Biologic therapies additionally require continuous use to avoid recurrence,and currently cost many times more than existing medical or surgical therapies.展开更多
文摘目的比较白介素13(IL—13)在慢性鼻窦炎不伴鼻息肉(CRSsNP)和慢性鼻窦炎伴鼻息肉(CRSwNP)患者中的差异性表达。方法选取10例CRSsNP和20例CRSwNP患者作为研究对象。根据鼻窦CT反映的病变范围评估患者病情,采用模拟视觉量表(VAS)评估慢性鼻窦炎轻重程度;术后采用PCR法分析IL-13在CRSsNP和CRSwNP组患者鼻黏膜及息肉中的差异性表达。结果 CRSwNP组鼻息肉组织IL-13 m RNA表达明显高于临近黏膜及CRSsNP黏膜组织;CRSsNP组和CRSwNP组鼻窦黏膜组织IL-13 m RNA表达差异无统计学意义。结论 IL-13m RNA表达水平在CRSsNP和CRSwNP组患者鼻黏膜或息肉中存在差异;白介素13(IL—13)在慢性鼻窦炎伴鼻息肉的病理过程中发挥有重要的作用。
文摘Aspirin-exacerbated respiratory disease(AERD)patients with CRSwNP suffer from reduced quality of life,reduced economic productivity,and higher risk of depression and sleep dysfunction.These patients often require frequent medical and surgical therapy,including functional endoscopic sinus surgery for recalcitrant disease.Given this severity,anti-type 2 biologic treatments are being investigated for use in this subgroup of patients with CRSwNP,including Omalizumab and Dupilumab.Preliminary data suggests that SNOT-22 related quality of life improvements following treatment with biologies are comparable to the current standard of care in the short term,but there is a lack of long-term data and standardized regimen that makes direct comparison difficult.Biologic therapies additionally require continuous use to avoid recurrence,and currently cost many times more than existing medical or surgical therapies.
